The nation's highest court has rejected an appeal to overturn a $64.6 million antitrust judgment against Martin Shkreli after inflating the price of a lifesaving anti-infection drug.
Supreme Court justices on Oct. 7 rejected Mr. Shkreli's appeal without comments.
Mr. Shkreli, the former CEO of Vyera Pharmaceuticals (previously known as Turing Pharmaceuticals), became infamous and was once dubbed "pharma bro" for hiking the price of the drug Daraprim from about $17.50 per pill to $750 overnight, a more than 4,000% increase.
Mr. Shkreli was convicted of defrauding investors and sentenced in 2018 to seven years in prison; he served about five years. A federal judge also banned Mr. Shkreli from the pharmaceutical industry and ordered him to pay $64.6 million.
He appealed to the Supreme Court to overturn the penalty, which was imposed in January 2022 by the U.S. District Court for the Southern District of New York and upheld by the U.S. Court of Appeals for the 2nd Circuit in January.
He argued that the award would force him to return profits that went entirely to his company rather than to him, according to Bloomberg.
His challenge to the Supreme Court did not contest the lifetime pharma industry ban, according to the publication.